Nonetheless, a significant proportion of AR synthetic ligand experimental programmes remain in the preclinical stage, highlighting that further research is crucially needed, especially on the involvement of AR in the cardiovascular context, as well as realistic effects produced by AR ligands to inform potential therapeutic applications for IHD. The gene discussed is AR; the disease is myocardial ischemia.